Market Research &
China Insights
Navigate complex markets with confidence using our proprietary biopharma intelligence. From competitive landscapes to deal benchmarking, we provide the depth and currency needed to make informed strategic decisions.
What We Offer
- Proprietary biopharma landscape reports tailored to your therapeutic area of interest
- Competitive intelligence: who is developing what in China and where they are in the pipeline
- Regulatory pathway analysis: NMPA accelerated programs, orphan designations, and approval trends
- Deal comps and valuation benchmarking for cross-border transactions
- Market entry strategy support for companies entering or expanding in China
- China pricing, reimbursement, and commercial access analysis
- Policy and regulatory monitoring: BIOSECURE Act, FDA-NMPA harmonization, and more
- BioLink Weekly — weekly newsletter delivering curated deal and market intelligence
Report Types
Therapeutic Area Landscape
Comprehensive mapping of China-based assets in a specific indication, by company, stage, modality, and partnering status.
Deal Comp Analysis
Benchmarking of recent licensing transaction terms (upfront, milestones, royalties, territory) for a specific modality or stage.
Regulatory Pathway Report
Analysis of NMPA and FDA approval pathways relevant to your asset, including timelines, precedent decisions, and data requirements.
Market Entry Strategy
Assessment of the China market opportunity for a specific drug, including competitive landscape, pricing outlook, and partnership options.
BioLink Weekly
Every week, BioLink Weekly delivers curated deal intelligence, regulatory updates, and market analysis focused on the US-China biopharma corridor. Five issues published since March 2026 and growing.
Read BioLink WeeklyRequest a Research Engagement
Tell us your research question and we will propose a tailored deliverable.
Get in Touch